EORTC AML21: Ten-Day Decitabine Shows Comparable Long-Term Survival to 3+7 Chemotherapy in Older AML Patients

EORTC AML21: Ten-Day Decitabine Shows Comparable Long-Term Survival to 3+7 Chemotherapy in Older AML Patients

Ten-day decitabine produced long-term survival similar to standard 3+7 chemotherapy in older patients with acute myeloid leukemia (AML) fit for intensive treatment, according to the final analysis of the randomized phase 3 EORTC AML21 trial. Transplant rates and post-transplant survival were also similar between arms, including in decitabine-treated patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) without complete remission.

Reduced-Intensity Induction in Older AML Patients

Intensive induction chemotherapy remains an established approach for medically fit patients with AML. In older patients, treatment-related complications, including infections and prolonged toxicity, may prevent progression to potentially curative allogeneic HSCT. A 10-day decitabine schedule was investigated to achieve disease control with lower toxicity before transplantation.

EORTC AML21 compared this approach directly with standard daunorubicin and cytarabine induction. An earlier analysis after approximately four years of follow-up found similar overall survival between groups. Decitabine was also associated with fewer nonhematologic adverse events and less deterioration in health-related quality of life. The long-term analysis assessed the durability of these outcomes, including survival after transplantation and the influence of remission status at HSCT.

EORTC AML21: Study Design and Patient Characteristics

EORTC AML21 (NCT02172872) was an open-label trial conducted at 54 hospitals across nine European countries. It randomized 606 patients aged 60 years or older with newly diagnosed AML, an Eastern Cooperative Oncology Group performance status of 0-2, and eligibility for intensive chemotherapy.

Decitabine was given at 20 mg/m² daily for the first 10 days of a 28-day cycle, followed by 5- or 10-day cycles according to remission status. The 3+7 regimen consisted of daunorubicin 60 mg/m² on days 1-3 and cytarabine 200 mg/m² on days 1-7, followed by one to three additional cycles. Allogeneic HSCT after reduced-toxicity conditioning was strongly encouraged in both groups.

The median age was 68 years, and approximately one-third of patients were 70 or older. By European LeukemiaNet (ELN) 2022 criteria, 63% of evaluable patients had adverse-risk disease. Adverse-risk disease was more frequent in the 3+7 group (69% vs 58%).

The primary endpoint was OS from randomization. Secondary endpoints included progression-free survival, transplantation rates, and outcomes after HSCT.

EORTC AML21: Ten-Day Decitabine Shows Comparable Long-Term Survival to 3+7 Chemotherapy in Older AML Patients

Long-Term Survival

Decitabine and 3+7 Produce Similar Outcomes. After a median follow-up of 5.8 years, 6-year outcomes were:

  • OS: 23.7% with decitabine vs 25.5% with 3+7 (HR, 1.02; 95% CI, 0.84-1.22)
  • PFS: 18.3% vs 20.6% (HR, 1.06; 95% CI, 0.89-1.27)

The confidence intervals show no statistically established survival difference between the two induction strategies. The trial was not designed to establish formal noninferiority of decitabine.

Exploratory analysis suggested an age gradient in the effect of decitabine. The OS HR was 0.82 in patients 70 or older and 1.29 in those aged 60-64, but the trend did not reach conventional statistical significance (P=0.056).

Allogeneic HSCT: Comparable Transplant Rates and Six-Year Survival

Transplantation and post-transplant outcomes were similar between arms:

  • Transplanted on protocol: 40% with decitabine vs 39% with 3+7
  • Not in complete remission with complete or incomplete hematologic recovery (CR/CRi) at HSCT: 23% vs 9%
  • 6-year OS from transplantation: 41.6% vs 41.2%

The cumulative incidence of progression and of death without progression after HSCT was also similar. Among decitabine-treated patients, 6-year post-transplant OS was 41.9% in those in CR/CRi at HSCT (n=92) and 42.9% in those without CR/CRi (n=28).

Conventional morphological remission before transplantation may therefore not be an absolute prerequisite for long-term survival in selected patients receiving decitabine. The investigators observed late events after transplantation in the 3+7 group that were not seen in the decitabine group during the reported follow-up.

Genetic Risk: Potential Benefit in Adverse-Risk AML

Decitabine appeared relatively more favorable in adverse-risk AML than in favorable-risk disease, with intermediate-risk results falling between the two. The overall trend was not statistically significant.

CR/CRi rates with decitabine were somewhat lower than with 3+7 in favorable- and intermediate-risk disease. Remission rates were similar in the adverse-risk subgroup. The investigators described these subgroup findings as unpublished analyses.

The biological activity of hypomethylating agents in genetically adverse AML provides a rationale for this pattern, but the data do not establish a survival advantage for decitabine in any ELN-defined subgroup.

Measurable Residual Disease After Decitabine Induction

An associated analysis assessed measurable residual disease by multiparameter flow cytometry in patients treated at participating Italian centers. Ten-day decitabine produced MRD-negative responses in ~30% of assessed patients, using a threshold of 0.1%. In the reduced-toxicity group, allogeneic transplantation appeared necessary to prevent relapse irrespective of MRD status.

How EORTC AML21 Relates to Venetoclax-Based Induction Strategies

In a prospective study by the Gruppo Italiano Trapianto di Midollo Osseo, five-day decitabine plus venetoclax enabled 57% of patients to undergo HSCT, all in complete remission. A randomized phase 2 trial by Lu and colleagues compared the same combination with standard induction in patients aged 18-59 years. Overall outcomes were similar, and the transplantation rate was 44%.

The PARADIGM study, which compared azacitidine plus venetoclax with intensive induction, reported improved event-free survival with the venetoclax-based approach. Differences in patient age, treatment combinations, eligibility criteria, and study design prevent direct comparison with EORTC AML21.

Clinical Implications and Limitations

Similar transplantation rates show that lower-intensity induction did not close the path to HSCT, which was the premise of the trial design. The earlier safety and quality-of-life results favor considering decitabine when toxicity is a concern.

The trial was open-label, genetic-risk distribution was not fully balanced, and the transplantation analyses involved selected patients who reached HSCT. Decitabine was not compared with venetoclax-based combinations, which are increasingly relevant to induction decisions. The study population was fit for intensive chemotherapy, so the results should not be extrapolated directly to patients ineligible for intensive treatment.

EORTC AML21: Ten-Day Decitabine Shows Comparable Long-Term Survival to 3+7 Chemotherapy in Older AML Patients

Armen Gevorgyan
Fact checked by Armen Gevorgyan MD, Medical Oncologist
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist